Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
Tariffs, Tech, NATL: Reciprocal tariffs in Jeopardy?View: The Supereme Court justices appeared skeptical of the Trump administration's arguments that the Executive Branch has the power to levy broad reciprocal tariffs. While we would see a return to a pre-reciprocal tariff regimen as broadly positi
Our target declines to $800 from $900 on lower estimates. With that said, 4Q25 revenue guidance appears low, with both implied impression and pricing growth decelerating against easier comps. In the report, we also discuss the AI = Metaverse narrative that has taken hold, the addition of $30B of new debt and why we are ending share buybacks in our model.
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...
It has been a busy week with Nvidia’s comments in Washington and three hyperscalers reporting last night. Building on these updates, we have already formed a very insightful perspective on how AI infrastructure deployments are shaping up for next year. Please follow the link for our insight summarized on a single slide.
Moody's Ratings (Moody's) assigned Aa3 ratings to Meta Platforms, Inc.'s (Meta) proposed senior unsecured notes, which will be comprised of various maturities. Meta will use the proceeds from the proposed offering for general corporate purposes. The outlook remains unchanged at stable. RATINGS RAT...
Shipments in Q4 are expected to dip 10% Q/Q given reduced inventories to pull from and Samsung's ongoing conversion of older lines (which is weighing on output).Capex: The company is considering a significant increase in capex in 2026. DRAM - Management noted spend should skew towards DRAM. For DRA
Figure 1. 3Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusNote: 3Q revenue guide in the range of $42.5-$45.5B.Meta delivered strong 3Q results. Revenue in the quarter reached $51.2B (+26.2% Y/Y), ahead of consensus of $49.5B (+21.9% Y/Y) by ~4%. Revenue was well above the h
What’s New: In this first take following tonight’s results, we focus on: 1. Weakness driven by inline revenue outlook and ominous AI investment language 2. No big surprises in ad revenue, but short of the most bullish buyside expectations 3. Capex fears confirmed, but the door was also opened to a potential neo cloud business 4. First comments on 2026 expense growth spook
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...
DRAM demand growth: Forecast to rise from high-teens % in 2025 to 20%+ in 2026. Hynix is emphasizing its transition to 1C to support conventional DRAM demand (expected to represent >50% of Korean capacity by end of 2026) and its ramp of M15X to increase HBM output in 2026.NAND demand/supply grow
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.